astragaloside a has been researched along with Hyperglycemia in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hu, Y; Hu, Z; Liu, W; Pan, C; Tang, W | 1 |
| Leng, B; Nie, Q; Wang, H; Zhang, L; Zhu, L | 1 |
2 other study(ies) available for astragaloside a and Hyperglycemia
| Article | Year |
|---|---|
Astragaloside IV Alleviates Renal Tubular Epithelial-Mesenchymal Transition via CX3CL1-RAF/MEK/ERK Signaling Pathway in Diabetic Kidney Disease.
Topics: Animals; Chemokine CX3CL1; Diabetes Mellitus; Diabetic Nephropathies; Epithelial-Mesenchymal Transition; Fibrosis; Hyperglycemia; MAP Kinase Signaling System; Mice; Mitogen-Activated Protein Kinase Kinases; Saponins; Signal Transduction; Triterpenes | 2022 |
Astragaloside IV protects against hyperglycemia-induced vascular endothelial dysfunction by inhibiting oxidative stress and Calpain-1 activation.
Topics: Acetylcysteine; Animals; Aorta, Thoracic; Biomarkers; Calpain; Cysteine Proteinase Inhibitors; Diabetes Mellitus, Experimental; Dipeptides; Endothelium, Vascular; Human Umbilical Vein Endothelial Cells; Humans; Hyperglycemia; Male; Nitric Oxide; Nitric Oxide Synthase Type III; Oxidative Stress; Rats; Rats, Sprague-Dawley; Saponins; Streptozocin; Triterpenes; Vasodilation | 2019 |